HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
IMA
ImageneBio Inc
There isn't enough reported data to score IMA yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
IMA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
IMA's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
IMA PE Valuation
IMA has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
IMA Forward outlook
There aren't enough analyst estimates for IMA to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
IMA has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus IMA down 156%.
IMA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$8.19 | +$6.45 |
| Q2 2025 | -$7.80 | +$9.12 |
| Q1 2025 | -$10.44 | +$8.40 |
| Q4 2024 | -$12.24 | +$7.32 |
| Q3 2024 | -$14.64 | +$4.68 |
| Q2 2024 | -$16.92 | +$3.36 |
| Q1 2024 | -$18.84 | +$3.00 |
| Q4 2023 | -$19.56 | +$3.24 |
IMA is still losing money, but far less than before: $8.19 per share over the past year, against $22.80 at its worst in late 2022.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus down 100% for IMA.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
IMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $659K | -88% |
| Q3 2023 | $1.2M | -81% |
| Q2 2023 | $2M | +425% |
| Q1 2023 | $5.3M | +57% |
| Q4 2022 | $5.5M | -73% |
| Q3 2022 | $6.4M | +71% |
| Q2 2022 | $382K | -89% |
| Q1 2022 | $3.4M | -2.6% |
IMA's revenue has slid since its 2021 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2023 | -3324% | -3047 points |
| Q3 2023 | -1646% | -1367 points |
| Q2 2023 | -923% | +4562 points |
| Q1 2023 | -292% | +209 points |
| Q4 2022 | -277% | -291 points |
| Q3 2022 | -279% | +108 points |
| Q2 2022 | -5485% | -5127 points |
| Q1 2022 | -501% | -221 points |
IMA's operating margin was −3324% last quarter, down 3047 points from the same quarter a year ago, near the bottom of its range since 2021.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over IMA on cash generation, producing positive trailing cash flow while its opponent burns cash.
IMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.5M | +$17.1M |
| Q2 2026 | -$9.1M | -$5.7M |
| Q1 2026 | -$14.8M | -$4.2M |
| Q4 2023 | -$22.1M | -$4.2M |
| Q3 2023 | -$20M | -$1.6M |
| Q2 2023 | -$18.1M | +$1.3M |
| Q1 2023 | -$19.9M | -$119K |
| Q4 2022 | -$17.9M | -$4M |
IMA has burned cash in almost every quarter: −$41M over the past year, against −$63M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over IMA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
IMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.9% | +961K shares |
| 1 year | +326% | +13.1M shares |
| 3 years | +423% | +13.8M shares |
IMA has 17M diluted shares, up 326% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
IMA Net Leverage
IMA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
IMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.2 | Oversold |
| Stochastic | 6.5 | Oversold |
IMA's weekly RSI is 26 (oversold) and its Stochastic is 6 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
IMA PE vs Healthcare Sector
| Metric | IMA | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
IMA has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
IMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.18 | 17% below |
| 20 week MA | $4.95 | 30% below |
| 50 week MA | $5.63 | 39% below |
| 100 week MA | $9.77 | 65% below |
| 200 week MA | $23.0 | 85% below |
IMA is in a downtrend: it's below all five of its weekly moving averages, and 85% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
IMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $384.0 | $178.1 | -54% |
| 2022 | $178.1 | $34.2 | -81% |
| 2023 | $34.2 | $23.6 | -31% |
| 2024 | $23.6 | $18.5 | -22% |
| 2025 | $18.5 | $5.80 | -69% |
| 2026 YTD | $5.80 | $3.45 | -41% |
IMA has the edge over HIMS on returns for 2026, with the stronger performance.